The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH,
Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous
nephropathy. Acthar is a hormone that stimulates steroid production from small glands above
the kidneys. It has direct protective effects on the kidney and is currently approved by the
FDA to treat kidney disorders associated with proteins in the urine, but the mechanisms of
action are not entirely understood and will be studied in the present trial.